Comparative analysis of treatment outcomes and risk factors associated with different combination antimicrobial regimens in patients with multidrug-resistant Acinetobacter baumannii pneumonia
Frontiers in Cellular and Infection Microbiology · 19.06.2026 · 16
DOI: 10.3389/fcimb.2026.1819679 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 19.06.2026. Verfasst von Meng Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Affiliated Hospital of Qinghai University, Xining, Qinghai, China. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Drug Resistance, Multiple, Bacterial, Anti-Bacterial Agents, Acinetobacter Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Multidrug-resistant Acinetobacter baumannii (MDRAB) pneumonia is a major cause of mortality in hospital-acquired infections due to extensive drug resistance and limited therapeutic options. Optimizing treatment and identifying mortality-related factors are urgently needed.
Objective
To compare the efficacy of different antibacterial regimens in MDRAB pneumonia and determine independent risk factors for 28-day all-cause mortality.
Methods
This single-center retrospective cohort study included 142 MDRAB pneumonia patients from February 2022 to February 2025. Patients were divided into three groups: Group A, sulbactam-containing combinations (n = 63); Group B, polymyxins + tigecycline (n = 45); Group C, other regimens (n = 34). Outcomes included bacterial resistance patterns, 28-day mortality, dynamic PCT and CRP levels, APACHE II and SOFA scores, and lymphocyte subsets. Multivariate logistic regression identified mortality predictors.
Results
Group A showed the lowest resistance to cefoperazone/sulbactam (30.16%) and the highest sensitivity (71.43%, both P< 0.05). Group B had the highest tigecycline resistance (31.11%). The 28-day mortality rates were 39.68% (A), 60.00% (B), and 64.71% (C) (P = 0.028). Independent mortality predictors were APACHE II, SOFA, and CD4+/CD8+ ratio (all P< 0.01). On day 7, Group A had the lowest PCT, while Group C showed the smallest declines in PCT and CRP. Group A exhibited the highest CD4+/CD8+ ratio.
Conclusion
Sulbactam-based combination therapy was associated with improved pathogen clearance and survival in this retrospective cohort. Mortality is closely linked to initial disease severity and early organ dysfunction. Dynamic changes in PCT and CD4+/CD8+ ratio have significant prognostic value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Affiliated Hospital of Qinghai University, Xining, Qinghai, China.
- Department of Emergency and Critical Care, Jiading Branch of Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Department of Respiratory and Critical Care Medicine, Tongren People's Hospital, Tongren, Guizhou, China.
- Department of Emergency Medicine, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Zitieren
APA
Xu, M., Liu, M., Tang, X., & Wu, X. (2026). Comparative analysis of treatment outcomes and risk factors associated with different combination antimicrobial regimens in patients with multidrug-resistant Acinetobacter baumannii pneumonia. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1819679
Vancouver
Xu M, Liu M, Tang X, Wu X. Comparative analysis of treatment outcomes and risk factors associated with different combination antimicrobial regimens in patients with multidrug-resistant Acinetobacter baumannii pneumonia. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1819679
BibTeX
@article{Xu2026,
author = {Xu, Meng and Liu, Mingxing and Tang, Xuebin and Wu, Xiaoying},
title = {Comparative analysis of treatment outcomes and risk factors associated with different combination antimicrobial regimens in patients with multidrug-resistant Acinetobacter baumannii pneumonia},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1819679}
}
EUVIMED